oVRcome has received IRB approval of our study to investigate the ability of virtual reality to function as a novel distraction intervention and improve the experience of patients who are receiving chemotherapy in the infusion clinic. The study will deploy and evaluate VR as an intervention for stress, pain, and negative affect in a cohort of 100 patients receiving chemotherapy.
Measures of interest include behavioral questionnaires regarding stress, pain, and negative affect, as well as heart rate and cyber sickness. For more details, view the clinicaltrials.gov page here!